The U.S. Supreme Court’s recent decision to overturn the Chevron doctrine has significant implications for the authority of regulatory agencies like the Food and Drug Administration (FDA). In its June 28 opinion in Loper Bright Enters. v. Raimondo, the Court ended the decades-old principle established by Chevron v. Natural Resources Defense Council, which had allowed courts to defer to federal agencies’ reasonable interpretation of ambiguous statutes.
This ruling is anticipated to provoke a wave of litigation targeting the FDA, particularly concerning its power to grant drug exclusivity and review tobacco marketing applications. By removing the deference previously given to the FDA’s interpretations of its regulatory authority, stakeholders may increasingly challenge the agency’s decisions in court.
For instance, the concept of drug exclusivity, which grants pharmaceutical companies exclusive rights to market a drug for a certain period, might now be subject to reinterpretation by the judiciary rather than the FDA. Similarly, the review process for tobacco marketing applications, a contentious area due to public health concerns, could also see increased legal confrontations as a result of the Court’s decision.
The 1984 Chevron decision had established that federal courts should defer to a regulatory agency’s interpretation of an ambiguous statute as long as it was reasonable. The dismantling of this doctrine marks a substantial shift in the balance of power between the judiciary and federal agencies, impacting how rules and regulations are interpreted and enforced moving forward.
This shift could lead to a more hostile environment for regulatory bodies, compelling them to provide clearer justifications for their rulings and possibly stymying their flexibility and responsiveness to emerging issues. Legal professionals in the pharmaceutical and tobacco industries, among others, will need to closely monitor the ramifications of this ruling as it develops.
For a deeper examination of this legal shift and its implications for the FDA, read the full article on Bloomberg Law.